Mariam Khachatryan, Medical Oncology Fellow at Yeolyan Hematology and Oncology Center and Research Analyst at OncoDaily, shared a post on LinkedIn:
“Happy to share that our work has been published in the Journal of Clinical Oncology as part of the ASCO2026 Annual Meeting abstracts.
This large real-world meta-analysis included 31,580 patients with HR+/HER2− metastatic breast cancer treated with palbociclib, ribociclib, or abemaciclib.
Key findings
- Objective response rate was highest with ribociclib across the reported ethnic groups.
- Median progression-free survival varied by ethnicity and CDK4/6 inhibitor: 25.2 months for Asian patients on ribociclib, 27.7 months for White patients on palbociclib, and 17.0 months for Black patients on abemaciclib.
- Asian cohorts had the highest rates of grade 3+ neutropenia across all three CDK4/6 inhibitors.
- Asian patients also showed the highest rates of leukopenia and anemia across CDK4/6 inhibitors.
These findings support the need for prospective trials focused on underrepresented populations in HR+/HER2− metastatic breast cancer.
Grateful to Dr. Aruni Ghose for his guidance and support, and to all co-authors for their valuable contributions.”
Title: Ethnicity-based comparative analysis of treatment endpoints of 30,000 HR+/HER2− metastatic breast cancer patients on CDK4/6 inhibitors (palbociclib/ribociclib/abemaciclib).
Authors: Olivia Benny, Adan Khan, Arissa James, Joecelyn Tan, Isabella Koprivec, Aaron Benedict, Vriddhi Urs, Vahe Grigoryan, Mariam Khachatryan, Debbie Ramkeelawon, Alma Jbeili, Patricia Lapitan, Ishikaa Mukherjee, Disha Khanna, Yetunde Owoseni, Akash Maniam, Sarah Adomah, Aruni Ghose, Olubukola Ayodele
Read the Full Article.
Other artciles featuring Mariam Khachatryan on OncoDaily.